Patents by Inventor Douglas Antelman

Douglas Antelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating hyperproliferative disorders using retinoblastoma fusion proteins
    Patent number: 6902731
    Abstract: Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: June 7, 2005
    Assignee: Canji, Inc.
    Inventors: Douglas Antelman, Richard J. Gregory, Kenneth N. Wills
  • Retinoblastoma fusion proteins
    Patent number: 6379927
    Abstract: Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: April 30, 2002
    Assignee: Canji, Inc.
    Inventors: Douglas Antelman, Richard J. Gregory, Kenneth N. Wills
  • Retinoblastoma fusion polypeptides
    Patent number: 6074850
    Abstract: Fusions of the transcription factor E2F and the retinoblastoma protein RB are provided, along with methods of treatment of hyperproliferative diseases.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: June 13, 2000
    Assignee: Canji, Inc.
    Inventors: Douglas Antelman, Richard J. Gregory, Kenneth N. Wills